Plant ID: NPO1551
Plant Latin Name: Luffa aegyptiaca
Taxonomy Genus: Luffa
Taxonomy Family: Cucurbitaceae
NCBI TaxonomyDB:
3670
Plant-of-the-World-Online:
293060-1
Brazil; Madagascar; Bangladesh; Liberia; Sudan; Guinea; Cambodia; Malawi; Ethiopia; Rwanda; Somalia; Swaziland; Vanuatu; Nigeria; Bolivia; Cameroon; Cote d'Ivoire; Benin; Ghana; Cuba; Thailand; Venezuela; Senegal; Burkina Faso; Zimbabwe; China; Jordan; Dominican Republic; Sierra Leone; Eritrea; Netherlands; Uganda; Gambia; Tanzania; Indonesia; New Caledonia; Mauritius; Trinidad and Tobago; Mauritania; Gabon; South Korea; Guinea-Bissau; Mali; Yemen; Haiti; Jamaica; Albania; Angola; Chad; Mexico; South Africa; India; Djibouti; Congo; Mozambique; Colombia; Burundi; Kenya; Niger; Fiji; Zambia
ATP1A1; | |
RECQL; | |
CA2; CA1; CA12; CA9; CA7; CA3; CA14; CA5B; CA5A; CA4; CA6; | |
RORC; | |
ESR2; | |
TP53; STAT3; | |
SLCO4C1; SLCO1B1; | |
ITGAL; RAB9A; LMNA; NPC1; MAPT; PAX8; |
Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Hydrolase | ATP1A1 | Sodium/potassium-transporting ATPase alpha-1 chain | P05023 | CHEMBL1807 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
SLC superfamily of solute carriers | SLCO4C1 | Solute carrier organic anion transporter family member 4C1 | Q6ZQN7 | CHEMBL2073690 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | STAT3 | Signal transducer and activator of transcription 3 | P40763 | CHEMBL4026 |
Unclassified | ITGAL | Leukocyte adhesion glycoprotein LFA-1 alpha | P20701 | CHEMBL1803 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.853E-12 | 9.322E-09 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, RORC, TP53 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.118E-07 | 1.522E-04 | ATP1A1, CA2, CA4, CA9, SLCO1B1, SLCO4C1 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.739E-30 | 3.787E-26 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 4.313E-06 | 5.218E-03 | ATP1A1, ESR2, NPC1, RORC |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.821E-06 | 5.407E-03 | CA2, CA7 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.585E-24 | 1.044E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.104E-22 | 2.234E-18 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 2.405E-05 | 2.094E-02 | CA1, CA2 |
BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 2.640E-05 | 2.211E-02 | ATP1A1, CA2, CA9, NPC1, RORC, STAT3, TP53 |
MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 3.392E-05 | 2.547E-02 | ESR2, RORC, STAT3 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 4.876E-05 | 2.766E-03 | STAT3, RAB9A, TP53 |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.578E-04 | 3.156E-03 | STAT3, ITGAL, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 1.108E-04 | 2.953E-03 | PAX8, TP53 |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 6.914E-05 | 2.766E-03 | CA2, ATP1A1 |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 5.787E-04 | 7.269E-03 | STAT3, TP53 |
09150 Organismal Systems | 09154 Digestive system | hsa04971 | Gastric acid secretion | 7.269E-04 | 7.269E-03 | CA2, ATP1A1 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.138E-03 | 9.753E-03 | PAX8, STAT3, TP53 |
09150 Organismal Systems | 09152 Endocrine system | hsa04918 | Thyroid hormone synthesis | 6.694E-04 | 7.269E-03 | PAX8, ATP1A1 |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 6.694E-04 | 7.269E-03 | CA2, ATP1A1 |
09150 Organismal Systems | 09154 Digestive system | hsa04972 | Pancreatic secretion | 1.219E-03 | 9.753E-03 | CA2, ATP1A1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | ATP1A1; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ATP1A1; |
NA: NA | Congestive cardiac insufficiency | NA | ATP1A1; |
C00-D49: Neoplasms | Allergic conjunctivitis | C91.0, H10, H10.45, T78.4 | ITGAL; |
C00-D49: Neoplasms | Multiple myeloma | C90 | STAT3; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
H00-H59: Diseases of the eye and adnexa | Dry eye disease | H16.229 | ITGAL; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | ATP1A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ITGAL; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ATP1A1; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
NA: NA | Arrhythmias | NA | ATP1A1; |
C00-D49: Neoplasms | Cancer | C00-C96 | STAT3; ATP1A1; TP53; |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Renal transplantation | D89.8 | ITGAL; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | STAT3; TP53; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | STAT3; |
NA: NA | Edema | NA | CA2; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | ATP1A1; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ATP1A1; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | ITGAL; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperhidrosis | R61 | ATP1A1; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ITGAL; STAT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |